Nomura on Cipla
Buy, TP Rs 1195
Goa USFDA inspection: 3 repeat observations
As a base case, do not expect inspection outcome to have a material impact on earnings est
Have not factored any material contribution from gAbraxane in est, as there are uncertainty over generic approval
